IRCT20100413003698N2已完成3 期
Evalution the role of pentoxifylline in erythropoietin-resistant anemia in hemodialysis patients
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •having the age of 18 years and more
- •receiving HD treatments at least for 3 months
- •receiving 4-hour HD treatments 3 times per week a
- •hemoglobin (Hb)<11 in at least 2 consecutive tests in a month
- •no change in EPO dose for at least 1 month before starting the study.
排除标准
- •blood transfusion due to any reason in recent 3 months
研究者
相似试验
已完成
不适用
Effect of pentoxyphilin for reduce of erythropoietin needs in hemodialysis patiente with anemiaEns stage renal disease.End-stage renal diseaseIRCT201011102417N4Vice Chancellor for Research, Isfahan University of Medical Sciences50
已完成
2 期
Effect of pentoxifylline in reducing proteinuria in patients with type 2 of diabetesDiabete.Diabetic nephropathyIRCT2016111827097N2Ardebil University of Medical Sciences32
已完成
1 期
The effect of pentoxifylline on improving of anemia in hemodialysis patientsChronic kidney diseaseIRCT2014042117380N1Vice-chancellor for research -Shahid Sadoughi University of Medical Science60
进行中（未招募）
1 期
Pentoxifylline in EPOrWe shall study patients with renal failure on dialysis. We shall particularly focus on patients with evidence of erythopoeitin stimulating agent (ESA) resistance.MedDRA version: 14.1 Level: LLT Classification code 10014647 Term: End stage renal failure System Organ Class: 100000004857EUCTR2011-006168-30-GBR&D, Barts and The London NHS Trust84
尚未招募
3 期
Investigation of the effect of pentoxifylline on Covid-19IRCT20170609034406N8Tabriz University of Medical Sciences100